Title: Rosuvastatin
CAS Registry Number: 287714-41-4
CAS Name: (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid
Molecular Formula: C22H28FN3O6S
Molecular Weight: 481.54
Percent Composition: C 54.87%, H 5.86%, F 3.95%, N 8.73%, O 19.94%, S 6.66%
Literature References: HMG-CoA reductase inhibitor. Prepn: K. Hirai et al., EP 521471; eidem, US 5260440 (both 1993 to Shionogi); M. Watanabe et al., Bioorg. Med. Chem. 5, 437 (1997). Pharmacology: F. McTaggart et al., Am. J. Cardiol. 87, Suppl., 28B (2001). Comparative clinical trial with atorvastatin: M. Davidson et al., ibid. 89, 268 (2002); in metabolic syndrome: A. F. H. Stalenhoef et al., Eur. Heart J. 26, 2664 (2005); in African-American patients: K. C. Ferdinand et al., Am. J. Cardiol. 97, 229 (2006). Pharmacokinetics and pharmacogenetics in Asian and white ethnic groups: E. Lee et al., Clin. Pharmacol. Ther. 78, 330 (2005). Review of therapeutic potential: K. C. Ferdinand, Expert Opin. Pharmacother. 6, 1897-1910 (2005).
Properties: Partition coefficient (octanol/water): 0.13 (pH 7.0).
Log P: Partition coefficient (octanol/water): 0.13 (pH 7.0)
Derivative Type: Calcium salt
CAS Registry Number: 147098-20-2
Manufacturers' Codes: S-4522; ZD-4522
Trademarks: Crestor (AstraZeneca)
Molecular Formula: C44CaH54F2N6O12S2
Molecular Weight: 1001.14
Percent Composition: C 52.79%, Ca 4.00%, H 5.44%, F 3.80%, N 8.39%, O 19.18%, S 6.41%
Properties: White powder from water as the monohydrate; begins to melt at 155° with no definitive mp. [a]D24 +14.8° (c = 1.012 in 50% methanol). Sparingly sol in water, methanol; slightly sol in ethanol.
Optical Rotation: [a]D24 +14.8° (c = 1.012 in 50% methanol)
Therap-Cat: Antilipemic.
Keywords: Antilipemic; HMG CoA Reductase Inhibitors; HMG CoA Reductase Inhibitor.

Others monographs:
Penicillin V HydrabamineAmmonium SulfiteNitrogen FluorideCarbohydrazide
LappaconitineRhizopterinSulfur TetrafluoridePiketoprofen
NabiloneDimecrotic AcidQuinizarinTrimethylene Oxide
©2016 DrugLead US FDA&EMEA